Sanne de Jongh joined Gilde Healthcare in 2017 and focuses on the biopharmaceutical sector. She is involved in deal sourcing, assessment of investment cases and portfolio management. She represents Gilde on the board of Calypso Biotech B.V. and ADCendo ApS.
Prior to joining Gilde, Sanne was with Anterra Capital for three years, a global food and ag tech fund backed by Fidelity and Rabobank. Here she worked on several biotech investments, such as Caribou Biosciences (IPO on Nasdaq: CRBU), Enko Chem and Agrimetis.
She began her career at MS Ventures, the biopharma fund of Merck KGaA, where she reviewed early stage strategic investments and supported the portfolio companies.
Sanne earned a masters degree (cum laude) in Biochemistry from Delft University of Technology, with a specialization in Neurology at the LUMC, the Netherlands. She is a Dutch citizen based in Gilde’s Utrecht office.